ストックスクリーナーアプリを入手
108.62
1.50%
1.60
アフターアワーズ：
108.66
0.04
+0.04%
前日終値:
$107.02
開ける：
$107.87
24時間の取引高:
2.45M
Relative Volume:
0.66
時価総額：
$23.54B
収益：
$819.56M
当期純損益:
$-1.18B
株価収益率:
-18.91
EPS:
-5.7434
ネットキャッシュフロー:
$-951.64M
1週間 パフォーマンス:
-1.35%
1か月 パフォーマンス:
+13.38%
6か月 パフォーマンス:
-30.51%
1年 パフォーマンス:
+5.68%
1日の値動き範囲:
$106.41
$109.42
1週間の範囲:
$105.07
$111.60
52週間の値動き範囲:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Compare INSM vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
108.62 | 23.20B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
482.00 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
675.19 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
874.74 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.29 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.37 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2026-03-30 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-23 | 開始されました | Roth Capital | Buy |
| 2025-12-19 | 再開されました | Truist | Buy |
| 2025-12-04 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-08-20 | 開始されました | William Blair | Outperform |
| 2025-08-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 開始されました | Jefferies | Buy |
| 2025-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-23 | 開始されました | Truist | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-07-26 | 開始されました | Guggenheim | Buy |
| 2022-12-09 | 開始されました | Mizuho | Buy |
| 2022-12-07 | 開始されました | Barclays | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Buy |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2021-12-06 | 開始されました | JP Morgan | Overweight |
| 2021-10-19 | 再開されました | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-10-12 | 再開されました | Stifel | Buy |
| 2019-09-03 | 開始されました | Goldman | Buy |
| 2019-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-15 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2019-01-02 | 開始されました | Canaccord Genuity | Buy |
| 2018-08-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 開始されました | Goldman | Neutral |
| 2018-04-23 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 開始されました | Morgan Stanley | Overweight |
| 2018-01-18 | 開始されました | Credit Suisse | Neutral |
| 2017-09-05 | 繰り返されました | Evercore ISI | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-11 | 開始されました | Robert W. Baird | Outperform |
| 2016-03-15 | 開始されました | Stifel | Buy |
| 2015-11-09 | ダウングレード | UBS | Buy → Neutral |
| 2015-10-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-06-09 | 開始されました | Citigroup | Neutral |
| 2014-03-26 | 繰り返されました | HC Wainwright | Buy |
すべてを表示
Insmed Inc (INSM) 最新ニュース
INSM Initiated Coverage by BMO Capital -- Price Target Announced at $192 - GuruFocus
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
BMO Capital Initiates Insmed at Outperform With $192 Price Target - marketscreener.com
Is Insmed (INSM) Priced Too Richly For Its Phase 3 Progress? - Yahoo Finance
Insmed (INSM) Following TPIP 12 Month Data, Does The Valuation Still Stack Up - Yahoo Finance
BMO initiates Insmed stock with outperform rating on respiratory franchise potential - Investing.com Nigeria
Insmed Announces Positive 12-Month Data from OLE Study of Inhalation Solution for Pulmonary Arterial Hypertension - dicardiology.com
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Positive 12‑Month TPIP PAH Data Could Be A Game Changer For Insmed (INSM) - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Buy Insmed for a double, this analyst says - Cantech Letter
Investors’ Concerns Hurt Insmed Incorporated (INSM) Despite Better-Than-Expected Results - Yahoo Finance
Insmed stock price target maintained at $220 by H.C. Wainwright - Investing.com Canada
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3 - webull.com
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237 - Moomoo
Open-label extension drives home benefits of Insmed’s PAH therapy - BioWorld News
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $207 - Moomoo
Insmed stock price target maintained at $200 by Stifel on trial data - Investing.com Canada
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning - Benzinga
INSM: TPIP sustained robust efficacy and safety at 12 months, with 65% reaching refined low-risk status - TradingView
Insmed (INSM) Reports Promising 12-Month Results for TPIP in PAH Patients - GuruFocus
Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study - Yahoo Finance
INSM: TPIP sustained best-in-class efficacy and safety at 12 months, with 65% reaching low-risk status - TradingView
Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients - Moomoo
Insmed reports 12-month data for PAH treatment candidate By Investing.com - Investing.com Canada
Insmed reports 12-month data for PAH treatment candidate - Investing.com
Insmed reports positive 12-month OLE results for TPIP showing sustained 6MWD, ~60% NT-proBNP drop - TradingView
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension - PR Newswire
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
INSM Maintained by Wells Fargo -- Price Target Raised to $161 - GuruFocus
William Haggerty Joins Insmed Incorporated as Senior Director of People Operations - hrtoday.in
Enterprise value to EBIT forward of Insmed Incorporated – BMV:INSM - TradingView
MSN Money - MSN
What's Driving Insmed's Recent Volatility - Kavout | AI
Enterprise value to revenue forward of Insmed Incorporated – BMV:INSM - TradingView
Insmed CEO William Lewis sells over $1.25m in company stock - Investing.com Australia
Insmed CEO William Lewis sells over $1.25m in company stock By Investing.com - Investing.com India
Insmed Insider Sold Shares Worth $1,256,084, According to a Recent SEC Filing - Moomoo
Form 4 Insmed Inc For: 10 July By Investing.com - Investing.com South Africa
INSMED Inc (NASDAQ: INSM) CEO executes 10b5-1 option exercise and sale of 10,699 shares - Stock Titan
INSM Reiterated by Guggenheim -- Price Target Maintained at $207 - GuruFocus
Insmed Slides 4% as Investors Weigh Insider Filing and Near-Term Catalyst Gap - Moomoo
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $207 - Moomoo
Form 144 INSMED INC For: 9 July By Investing.com - Investing.com India
INSM (NASDAQ: INSM) affiliate William Lewis reports multiple share sales - Stock Titan
INSM Technical Analysis & Stock Price Forecast - Intellectia AI
Insmed CMO Martina Flammer sells $1.35m in stock - Investing.com
Insmed (NASDAQ:INSM) Drug Launch Fuels Healthcare Market Buzz - Kalkine Media
Insmed Inc (INSM) 財務データ
収益
当期純利益
現金流量
EPS
0.29%
0.48%
大文字化:
|
ボリューム (24 時間):